Value Sense
LEGN
Legend Biotech Corporation (LEGN)
Last Price$37.29.3%
Market Cap$3,309.7M
LTM Cash Flow from Operating Activities
($154.5M)
YoY Growth
-55.5%
3Y CAGR
-5.8%
5Y CAGR
+46.3%
Stock quality & Intrinsic value
6/10
83.7% undervalued
LEGN
is 83.7% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Legend Biotech Corporation Cash Flow from Operating Activities

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Cash Flow from Operating Activities
($2,376.0K)
$307.7M
($83.1M)
($223.0M)
($198.5M)
($200.0M)
($393.3M)
LEGN
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for LEGN and see if it's the right time to invest.
Dive in

Legend Biotech Corporation (LEGN) Cash Flow from Operating Activities comparison analysis

General

LTM Cash Flow from Operating Activities

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Legend Biotech Corporation logo
Legend Biotech CorporationLEGN
($154.5M)
(55.5%)
(5.8%)
46.3%
Median Peer Set
$108.2M
(1.9%)
(7.3%)
0.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
$4,420.5M
(3.8%)
(14.5%)
12.7%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
$2,769.0M
(7.3%)
11.1%
29.2%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
$1,327.1M
35.7%
30.4%
N/A
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
$572.8M
259.7%
23.4%
64.0%
BioNTech SE logo
BioNTech SEBNTX
$224.7M
(96.1%)
(38.4%)
N/A
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
($8,312.0K)
N/A
(76.5%)
(50.5%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
($142.0M)
84.9%
25.1%
44.9%
argenx SE logo
argenx SEARGX
($145.5M)
(76.5%)
(30.4%)
N/A
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
($437.4M)
(65.1%)
(27.0%)
(8.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
($492.6M)
N/A
N/A
N/A

LEGN key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
23.6
0.0%
49.1
108.2%
57.3
16.5%
75.7
32.2%
89.8
18.7%
117.0
30.3%
285.1
143.7%
Cost of Goods Sold (COGS)(0.1)0.00.0232.2313.365.4144.2
Gross Profit
% margin
23.7
100.4%
49.1
100.0%
57.3
100.0%
(156.5)
(206.8%)
(223.6)
(249.0%)
51.6
44.1%
140.9
49.4%
Operating Expenses9.664.2192.6304.9462.8509.7140.9
Research & Development Expenses (R&D)8.260.6161.9232.2313.3335.6382.2
Selling, General & Administrative Expenses (SG&A)1.43.932.472.7149.5174.0200.9
Operating Income
% margin
13.8
58.4%
(1.5)
(3.1%)
(130.9)
(228.5%)
(313.3)
(414.1%)
(393.0)
(437.7%)
(455.8)
(389.6%)
(439.5)
(154.1%)
Interest Income0.06.24.62.91.08.254.5
Interest Expense0.00.10.24.20.910.821.8
Pre-tax Income13.8(1.6)(130.4)(307.6)(386.2)(445.7)(520.1)
Income Tax
% effective tax rate
4.5
32.3%
1.2
(72.3%)
2.6
(2.0%)
(4.1)
1.3%
0.0
(0.0%)
0.6
(0.1%)
(1.9)
0.4%
Net Income
% margin
9.4
39.7%
(2.8)
(5.7%)
(133.0)
(232.2%)
(303.5)
(401.0%)
(386.2)
(430.1%)
(446.3)
(381.5%)
(518.3)
(181.8%)
EPS0.07(0.03)(1.01)(2.57)(2.74)(2.81)(2.94)
Diluted EPS0.07(0.03)(1.01)(2.57)(2.74)(2.81)(2.94)
EBITDA
% margin
14.1
59.6%
0.1
0.3%
(124.9)
(218.1%)
(294.1)
(388.7%)
(392.4)
(437.0%)
(416.5)
(356.0%)
(477.9)
(167.6%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Legend Biotech Corporation's Cash Flow from Operating Activities?

As of today, Legend Biotech Corporation's last 12-month Cash Flow from Operating Activities is ($154.5M), based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Legend Biotech Corporation's Cash Flow from Operating Activities growth rate?

Over the last year, Legend Biotech Corporation's Cash Flow from Operating Activities growth was (55.5%). The average annual Cash Flow from Operating Activities growth rates for Legend Biotech Corporation have been (8.8%) over the past three years, 46.3% over the past five years.

3) Is Legend Biotech Corporation's Cash Flow from Operating Activities growth rate Good?

Over the last year, Legend Biotech Corporation's Cash Flow from Operating Activities growth was (55.5%), which is lower than industry growth of (0.0%). It indicates that Legend Biotech Corporation's Cash Flow from Operating Activities growth is Bad.

4) How does Legend Biotech Corporation's Cash Flow from Operating Activities growth rate compare to its peers?

Over the last year, Legend Biotech Corporation's Cash Flow from Operating Activities growth was (55.5%), which is higher than peer median growth of (81.0%). The list of peers includes REGN, RPRX, UTHR, BMRN, BNTX, ALNY, SMMT, ARGX, BGNE, VRTX etc.